A bill that got a boost of momentum right before the end of the 2024 legislative session tries to keep lower- priced prescription drugs accessible to lower income Marylanders.
The board is considering studying eight name brand prescription drugs that treat a variety of diseases, including diabetes, HIV, and attention-deficit/hyperactivity disorder (ADHD).
Bill would allow the board to implement upper payment limits for prescription drug purchases and payer reimbursements if the state finds that certain drugs are ‘unaffordable.’
Health care advocates believe the report supports their call to expand authority of a state board that aims to lower drug costs for Marylanders.
A state board tasked with controlling prescription drug prices for Maryland workers said that they are likely to identify the first set of medications…
Seniors and uninsured people who have diabetes pay far more for insulin and their other medications than they should, a new congressional report concludes, because federal…